| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 64636 |
|
1,851 |
1,379 |
$1.48M |
| 64635 |
|
1,847 |
1,378 |
$846K |
| L0648 |
Lumbar-sacral orthosis, sagittal control, with rigid anterior and posterior panels, posterior extends from sacrococcygeal junction to t-9 vertebra, produces intracavitary pressure to reduce load on the intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf |
710 |
611 |
$394K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
13,738 |
11,596 |
$317K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
4,943 |
4,425 |
$194K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,769 |
1,565 |
$70K |
| 80332 |
|
2,391 |
2,104 |
$42K |
| 80338 |
|
2,375 |
2,090 |
$41K |
| 80324 |
|
2,430 |
2,114 |
$37K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
832 |
714 |
$34K |
| 62323 |
|
157 |
140 |
$30K |
| 64493 |
|
192 |
158 |
$22K |
| L0637 |
Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panels, posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panels, produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise |
32 |
29 |
$18K |
| 99152 |
|
587 |
479 |
$15K |
| 64495 |
|
192 |
158 |
$8K |
| 64494 |
|
192 |
158 |
$8K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
79 |
68 |
$1K |
| 80347 |
|
84 |
82 |
$1K |
| 80364 |
|
84 |
82 |
$1K |
| 20552 |
|
16 |
15 |
$875.05 |
| 80370 |
|
84 |
82 |
$868.68 |
| 80368 |
|
126 |
96 |
$718.78 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
611 |
583 |
$711.10 |
| 83992 |
|
55 |
27 |
$139.44 |
| 80356 |
|
13 |
13 |
$125.94 |
| 80358 |
|
55 |
27 |
$67.04 |
| 80355 |
|
56 |
28 |
$65.34 |
| 80361 |
|
55 |
27 |
$41.98 |
| 80365 |
|
55 |
27 |
$27.02 |
| 80359 |
|
55 |
27 |
$24.45 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
17 |
15 |
$8.48 |
| 80363 |
|
42 |
14 |
$0.00 |
| 80333 |
|
42 |
14 |
$0.00 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
58 |
54 |
$0.00 |
| 80350 |
|
42 |
14 |
$0.00 |
| 80353 |
|
42 |
14 |
$0.00 |
| 80367 |
|
55 |
27 |
$0.00 |
| 80345 |
|
13 |
13 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
198 |
159 |
$0.00 |
| 80354 |
|
42 |
14 |
$0.00 |
| 80346 |
|
42 |
14 |
$0.00 |
| 80372 |
|
52 |
27 |
$0.00 |
| 80373 |
|
55 |
27 |
$0.00 |
| 80336 |
|
49 |
26 |
$0.00 |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
18 |
16 |
$0.00 |
| 80369 |
|
42 |
14 |
$0.00 |
| 80366 |
|
42 |
14 |
$0.00 |
| G9622 |
Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method |
16 |
13 |
$0.00 |
| 80348 |
|
39 |
13 |
$0.00 |
| G8482 |
Influenza immunization administered or previously received |
28 |
26 |
$0.00 |